Tracking Results of Ablations to Combat AF Registry Generation 2
← catalyst calendarNCT05111015 · readout ≤ 4,912 d
Sponsored by AtriCure, Inc. (industry) · ATRC — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
10,000estimated
Sites
29
Countries
Austria, Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-03-11 | actual | When the study began enrolling |
| Primary completion | Jan 2040 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2040 | estimated | The whole study's end, after follow-up |
| First posted | 2021-11-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Atrial Fibrillation
Interventions
- Device: Open Concomitant Surgical Ablation Procedures
- Device: Hybrid (Convergent) Ablation Procedures
- Device: AtriCure Hybrid Totally Thoracoscopic Ablation Procedures
- Device: AtriCure LAA Exclusion Procedures
Primary outcomes
what the primary-completion date above is the date OFPatient's AF burden 6-month after receiving the ablation procedure
measured 6 months
Adverse events of the ablation procedure as atrial fibrillation management
measured 1 year
Permalink · ATRC's whole pipeline · Catalyst calendar · Every registered study · What changed